Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Clinical trial NCT03474965 · COMPLETED
Trial details
- NCT number
- NCT03474965
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-01
- Primary completion
- 2024-11-06
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.